Uni-Bio Science Group Ltd
HKEX:690
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Uni-Bio Science Group Ltd
Operating Income
Uni-Bio Science Group Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Uni-Bio Science Group Ltd
HKEX:690
|
Operating Income
HK$102.8m
|
CAGR 3-Years
31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hbm Holdings Ltd
HKEX:2142
|
Operating Income
$82.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
China Regenerative Medicine International Ltd
HKEX:8158
|
Operating Income
HK$16.4m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CK Life Sciences Intl (Holdings) Inc
HKEX:775
|
Operating Income
-HK$66.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
SinoMab BioScience Ltd
HKEX:3681
|
Operating Income
-¥107.5m
|
CAGR 3-Years
25%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Essex Bio-Technology Ltd
HKEX:1061
|
Operating Income
HK$418.7m
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Uni-Bio Science Group Ltd
Glance View
Uni-Bio Science Group Ltd. is an investment holding company with interests in pharmaceutical research and development. The company employs 326 full-time employees The company went IPO on 2001-11-12. The firm operates through four segments. In-house Chemical Pharmaceutical Products segment is engaged in the manufacture and sales of in-house chemical pharmaceutical products. Its chemical pharmaceutical products include Pinapu, among others. In-house Biological Pharmaceutical Products segment is engaged in the manufacture and sales of in-house biological pharmaceutical products. Its biological pharmaceutical products include GeneTime and GeneSoft, among others. In-house Biological Pipeline segment is engaged in the industrialization of in-house biological pipeline. Its biological pipeline products include Uni-E4 and Uni-PTH, among others. Third-party Pharmaceutical Products segment is engaged in the sales of third-party pharmaceutical products.
See Also
What is Uni-Bio Science Group Ltd's Operating Income?
Operating Income
102.8m
HKD
Based on the financial report for Dec 31, 2025, Uni-Bio Science Group Ltd's Operating Income amounts to 102.8m HKD.
What is Uni-Bio Science Group Ltd's Operating Income growth rate?
Operating Income CAGR 3Y
31%
Over the last year, the Operating Income growth was 15%. The average annual Operating Income growth rates for Uni-Bio Science Group Ltd have been 31% over the past three years .
